Skip to content

Plasma neutrophil gelatinase-associated lipocalin is independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Journal
PLOS ONE13(10) · 2018
Citation
Web of Science 16Scopus 19
FWCI (Scopus)
0.43
JCR IF
JCR 2017 2.766
ISSN
1932-6203

Authors

  1. Kim, Il-youngFirst authorDepartment of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea
  2. Kim, June HyunDepartment of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea
  3. Kim, Min JeongDepartment of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea
  4. Lee, Dong-wonDepartment of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea
  5. Hwang, Cheol GuMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  6. Han, MiyeunMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  7. Rhee HarinMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  8. Sang Heon SongMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  9. Seong, Eun-youngMedical Research Institute, Pusan National University Hospital, Busan, South Korea
  10. Lee, Soo BongCorresponding authorDepartment of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea

Abstract

Background Cardiovascular disease (CVD) is a leading cause of death in patients with chronic kidney disease (CKD). Left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD) are known as predictors of CVD in these patients. Neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker of acute kidney injury. Recently, elevated NGAL levels have been reported in patients with CVD. This study aimed to evaluate the association between plasma NGAL levels and LVH/LVDD in patients with CKD. Methods This study included 332 patients with pre-dialysis CKD (estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m(2)). Two-dimensional echocardiography was performed to measure the left ventricular mass index (LVMI). Tissue Doppler imaging was used to measure early mitral inflow velocity (E) and the peak early mitral annular velocity (E'). Diastolic function was estimated using E' and the ratio of E to E' (E/E'). The associations of echocardiographic index with clinical and laboratory variables (age, sex, diabetes, hypertension, eGFR, albumin, uric acid, calcium, phosphate, total cholesterol, hemoglobin, C-reactive protein, intact parathyroid hormone (PTH), the inferior vena cava collapse index (IVCCI) < 50%, and plasma NGAL) were investigated using univariate and multivariate analyses. Results In multivariate logistic regression analysis, plasma NGAL was an independent predictor of LVH (OR: 1.02, 95% CI: 1.01-1.02), P < 0.001). In addition, hypertension, intact PTH, and IVCCI < 50% were independent predictors of LVH. Plasma NGAL (OR: 1.02, 95% CI: 1.01-1.02, P < 0.001) was also an independent factor of LVDD. Furthermore, hypertension, intact PTH, and IVCCI < 50% were independent predictors of LVDD. Receiver operating characteristic curve analysis (area under the curve: 0.835, 95% CI: 0.792-0.879) showed the best cutoff value of plasma NGAL for identifying LVDD was >= 258 ng/ml with an associated sensitivity of 77.6% and a specificity of 87.6%. Conclusion Plasma NGAL levels were independent predictors of LVH and LVDD in patients with predialysis CKD, suggesting that plasma NGAL could be a biomarker for LVH and LVDD in these patients.

Keywords

CORONARY-ARTERY-DISEASECHRONIC HEART-FAILURECARDIOVASCULAR-DISEASELEUKOCYTE ACTIVATIONNGALMORTALITYMARKERDAMAGECKD

Identifiers

Scopus EID
2-s2.0-85055077528
WoS UID
000447430800046